InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

- Current share price for LDX : $0.125

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$118 Application for quotation of securities - LDX 2 Apr 2026 12:00PM $0.230 $0.125 fallen by 45.65%
$118 Lumos receives largest FebriDx order to date 1 Apr 2026 10:47AM $0.230 $0.125 fallen by 45.65%
$118 Investor Briefing Invitation 27 Mar 2026 4:33PM $0.255 $0.125 fallen by 50.98%
$118 Investor Presentation 27 Mar 2026 10:13AM $0.265 $0.125 fallen by 52.83%
$118 Proposed issue of securities - LDX 27 Mar 2026 10:08AM $0.265 $0.125 fallen by 52.83%
$118 Proposed issue of securities - LDX 27 Mar 2026 10:08AM $0.265 $0.125 fallen by 52.83%
$118 Lumos completes $20m placement and launches SPP 27 Mar 2026 10:08AM $0.265 $0.125 fallen by 52.83%
$118 US FDA Grants CLIA Waiver for FebriDx 27 Mar 2026 10:08AM $0.265 $0.125 fallen by 52.83%
$118 Trading Halt 25 Mar 2026 9:21AM $0.265 $0.125 fallen by 52.83%
$118 Section 708A Cleansing Statement 5 Mar 2026 9:34AM $0.275 $0.125 fallen by 54.55%
$118 Application for quotation of securities - LDX 5 Mar 2026 9:32AM $0.275 $0.125 fallen by 54.55%
$118 1H FY26 Results Investor Presentation 3 Mar 2026 10:31AM $0.275 $0.125 fallen by 54.55%
$118 Lumos Delivers Several Pivotal Milestones in 1H FY26 27 Feb 2026 9:49AM $0.255 $0.125 fallen by 50.98%
$118 Appendix 4D and Half Year Report 27 Feb 2026 9:47AM $0.255 $0.125 fallen by 50.98%
$118 Lumos Completes Enrolment Milestone for Paediatric Study 23 Feb 2026 9:45AM $0.280 $0.125 fallen by 55.36%
$118 Section 708A Cleansing Statement 6 Feb 2026 9:06AM $0.260 $0.125 fallen by 51.92%
$118 Application for quotation of securities - LDX 6 Feb 2026 9:03AM $0.260 $0.125 fallen by 51.92%
$118 Q2 FY26 Results Investor Presentation 3 Feb 2026 9:27AM $0.230 $0.125 fallen by 45.65%
$118 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 2:22PM $0.195 $0.125 fallen by 35.90%
$118 Lumos secures follow on contract with Aptatek 19 Jan 2026 10:48AM $0.285 $0.125 fallen by 56.14%
$118 Section 708A Cleansing Statement 9 Jan 2026 5:01PM $0.310 $0.125 fallen by 59.68%
$118 Application for quotation of securities - LDX 9 Jan 2026 4:58PM $0.310 $0.125 fallen by 59.68%
$118 Investor Webinar Invitation-Reducing Diagnostic Uncertainty 7 Jan 2026 12:20PM $0.295 $0.125 fallen by 57.63%
$118 Lumos Secures Distribution for FebriDx in Baltic Region 18 Dec 2025 12:07PM $0.245 $0.125 fallen by 48.98%
$118 Section 708A Cleansing Statement 21 Nov 2025 1:22PM $0.185 $0.125 fallen by 32.43%

51 - 75 of 544 results

Page 3 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.